|
AU2015201194A1
|
|
Drugs with improved hydrophobicity for incorporation in medical devices
|
|
AU2012202903A1
|
|
Drugs with improved hydrophobicity for incorporation in medical devices
|
|
WO2009015293A1
|
|
Method for measuring the concentration of a glycosaminoglycan anticoagulant
|
|
EP2120964A2
|
|
Triazine derivatives and their therapeutical applications
|
|
WO2008061134A1
|
|
Derivatives of 18-amino substituted analogs of the geldamycin hydroquinon with cytotoxic activity for the treatment of cancer
|
|
WO2008021186A2
|
|
Web based integrated information system for sharing patient medical information cross-organizationally
|
|
WO2007059116A2
|
|
Geldanamycin derivatives and pharmaceutical compositions thereof
|
|
EP1976505A1
|
|
Combretastatin derivatives and related therapeutic methods
|
|
TW200810745A
|
|
Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
|
|
CN101568332A
|
|
Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
|
|
CA2598510A1
|
|
Q3 sparc deletion mutant and uses thereof
|
|
CA2598159A1
|
|
Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
|
|
US2008171687A1
|
|
Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
|
|
CN1980699A
|
|
Treatment methods utilizing albumin-binding proteins as targets
|
|
CA2565296A1
|
|
Sustained-release microspheres and methods of making and using same
|
|
CA2551567A1
|
|
Propofol analogs, process for their preparation, and methods of use
|
|
EP1715921A2
|
|
Tetrahydroindolone derivatives for treatment of neurological conditions
|
|
NZ541142A
|
|
Compositions and methods of delivery of pharmacological agents
|
